Clinical Trial Update: Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating immunotherapy with SBRT to sensitize PD-1 in metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Small Cell Lung Cancer

Snippet

Sponsor: Crozer-Keystone Health System | Conditions: Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED